SAA3P and diabetic kidney disease: To monitor diabetic kidney disease in the HFD/multiple low-dose STZ-induced DN model, we performed in vivo bioluminescence imaging with Saa3 promoter-luciferase transgenic mice (Saa3 promoter-luc mice) eight weeks after diabetic induction.